Acorda Therapeutics, Inc. (NASDAQ:ACOR)

CAPS Rating: 2 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Recs

0
Player Avatar doohoo (< 20) Submitted: 7/1/2010 4:05:46 PM : Outperform Start Price: $29.88 ACOR Score: -52.70

Recent launch of new drug already improved earnings vs 2009, several potential high earning drugs in pipeline.

Featured Broker Partners


Advertisement